Bio-Techne (TECH) Operating Income (2009 - 2026)
Bio-Techne (TECH) posted quarterly Operating Income of $75.5 million for Q1 2026, up 95.04% year-over-year from $38.7 million in Q1 2025, and up 38.62% quarter-over-quarter from $54.5 million in Q4 2025.
Bio-Techne (TECH) Operating Income (2009 - 2026) Analysis & Trends
Bio-Techne's Operating Income history runs 18 years deep, the most recent figure standing at $75.5 million for Q1 2026.
- In Q1 2026, Operating Income rose 95.04% year-over-year to $75.5 million; the TTM figure through Mar 2026 stood at $153.8 million (down 10.58% YoY), while the FY2025 annual figure was $102.3 million, down 50.53% from the prior year.
- Operating Income for Q1 2026 stood at $75.5 million, up from $54.5 million in the prior quarter.
- The five-year high for Operating Income was $94.5 million in Q2 2023, with the low at -$23.9 million in Q2 2025.
- The 5-year median for Operating Income is $55.9 million (2023), against an average of $56.3 million.
- The sharpest annual moves came in 2025 and 2026: Operating Income slumped 152.07% in 2025, then jumped 95.04% in 2026.
- Bio-Techne's Operating Income stood at $67.9 million in 2022, then tumbled by 44.02% to $38.0 million in 2023, then climbed by 24.77% to $47.4 million in 2024, then gained by 14.85% to $54.5 million in 2025, then jumped by 38.62% to $75.5 million in 2026.
- Business Quant data shows TECH's Operating Income at $75.5 million in Q1 2026, $54.5 million in Q4 2025, and $47.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 75.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.50 Mn |
| Dec 31, 2025 | 54.46 Mn |
| Sep 30, 2025 | 47.66 Mn |
| Jun 30, 2025 | -23.86 Mn |
| Mar 31, 2025 | 38.71 Mn |
| Dec 31, 2024 | 47.42 Mn |
| Sep 30, 2024 | 39.99 Mn |
| Jun 30, 2024 | 45.82 Mn |
| Mar 31, 2024 | 67.00 Mn |
| Dec 31, 2023 | 38.00 Mn |
| Sep 30, 2023 | 55.86 Mn |
| Jun 30, 2023 | 94.53 Mn |
| Mar 31, 2023 | 80.21 Mn |
| Dec 31, 2022 | 67.89 Mn |
| Sep 30, 2022 | 56.32 Mn |
| Jun 30, 2022 | 80.57 Mn |
| Mar 31, 2022 | 90.45 Mn |
| Dec 31, 2021 | 62.35 Mn |
| Sep 30, 2021 | 63.22 Mn |
| Jun 30, 2021 | 68.58 Mn |